leukocyte immunoglobulin like receptor B1 (CD85j)
Target has curated data in GtoImmuPdb
Target id: 2973
Nomenclature: leukocyte immunoglobulin like receptor B1 (CD85j)
Abbreviated Name: LILRB1
Contents:
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 1 | 650 | 19q13.42 | LILRB1 | leukocyte immunoglobulin like receptor B1 | |
| Gene and Protein Information Comments | ||||||
| Multiple transcript variants encoding different isoforms have been found for the human gene. We provide the RefSeqs and gene/protein information for isoform 1. | ||||||
| Previous and Unofficial Names |
| ILT2 | leucocyte Ig-like receptor B1 | leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 | LIR-1 | LIR1 | MIR-7 | myeloid inhibitory receptor 7 | PIR-B | PIRB |
| Database Links |
|
| Alphafold | Q8NHL6 (Hs) |
| Ensembl Gene | ENSG00000104972 (Hs) |
| Entrez Gene | 10859 (Hs) |
| Human Protein Atlas | ENSG00000104972 (Hs) |
| KEGG Gene | hsa:10859 (Hs) |
| OMIM | 604811 (Hs) |
| Pharos | Q8NHL6 (Hs) |
| RefSeq Nucleotide | NM_006669 (Hs) |
| RefSeq Protein | NP_006660 (Hs) |
| UniProtKB | Q8NHL6 (Hs) |
| Wikipedia | LILRB1 (Hs) |
| Immunopharmacology Comments |
| LILRB1 (CD85j) is a member of the inhibitory leukocyte immunoglobulin like receptor (LILRB) family (HGNC family 1182). It acts as an inhibitory immune checkpoint for B cell function. Ligands identified for LILRB include native MHC class I proteins, some HLA molecules, pathogen-derived ligands (e.g. from CMV, Dengue virus and some bacteria) and host immunomodulatory proteins such as S100 calcium binding protein A9 (S100A9; P06702; which also binds TLR4 and RAGE) [2]. Expression of LILRB1 by macrophages (including tumour-associated macrophages) facilitates binding to MHC class I, and this interaction mediates an inhibitory signal that negatively regulates phagocytosis [1]. In addition, cancer cells that express LILRB1 are protected from macrophage phagocytosis, and when either LILRB1 or MHC class I expression by cancer cells is disrupted in vitro and in vivo, phagocytosis resumes. These findings suggest LILRB1 as a novel immuno-oncology target. LILRB1 has been identified as a potential molecular receptor for Plasmodium falciparum-coded proteins that are expressed by infected host erythrocytes. Interaction of these parasite RIFIN proteins (encoded by rif genes [3]) and inhibitory leukocyte receptors such as LILRB1 appears to mediate parasite-driven evasion of the host's immune system by inhibiting activation of LILRB1-expressing B cells and natural killer (NK) cells [6]. |
| Cell Type Associations | ||||||||
|
||||||||
|
| Immuno Process Associations | ||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
| Clinically-Relevant Mutations and Pathophysiology
|
||||||||||||||||||
|
||||||||||||||||||
| General Comments |
| LILRB1 binds to MHC class I molecules on human lymphoid and myelomonocytic cells, including natural killer (NK) cells,T cells, B cells, monocytes, macrophages, and dendritic cells [4]. This interaction mediates an inhibitory 'don't-eat-me' signal via cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) contained in the protein's intracellular domain, and this inhibits propagation of an immune response upon recognition of self-MHC class I molecules. |
References
1. Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM et al.. (2018) Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol, 19 (1): 76-84. [PMID:29180808]
2. Burshtyn DN, Morcos C. (2016) The Expanding Spectrum of Ligands for Leukocyte Ig-like Receptors. J Immunol, 196 (3): 947-55. [PMID:26802060]
3. Cheng Q, Cloonan N, Fischer K, Thompson J, Waine G, Lanzer M, Saul A. (1998) stevor and rif are Plasmodium falciparum multicopy gene families which potentially encode variant antigens. Mol Biochem Parasitol, 97 (1-2): 161-76. [PMID:9879895]
4. Colonna M, Navarro F, Bellón T, Llano M, García P, Samaridis J, Angman L, Cella M, López-Botet M. (1997) A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med, 186 (11): 1809-18. [PMID:9382880]
5. Lozano E, Díaz T, Mena MP, Suñe G, Calvo X, Calderón M, Pérez-Amill L, Rodríguez V, Pérez-Galán P, Roué G et al.. (2018) Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma. J Immunol, 200 (8): 2581-2591. [PMID:29531171]
6. Saito F, Hirayasu K, Satoh T, Wang CW, Lusingu J, Arimori T, Shida K, Palacpac NMQ, Itagaki S, Iwanaga S et al.. (2017) Immune evasion of Plasmodium falciparum by RIFIN via inhibitory receptors. Nature, 552 (7683): 101-105. [PMID:29186116]
How to cite this page
CD molecules: leukocyte immunoglobulin like receptor B1 (CD85j). Last modified on 15/05/2018. Accessed on 18/04/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2973.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License